Anti-FCV (feline calicivirus) feline-type recombinant antibody effective for treatment, prevention and diagnosis of FCV infection and a gene fragment useful for preparation of said antibody are provided. Cell line lD7 capable of producing a mouse monoclonal antibody having an excellent FCV-neutralizing activity was constructed and a gene fragment coding for the V region in charge of the FCV-specific binding of said antibody was obtained. This gene fragment and the gene coding for the constant region of the feline antibody are used to give a chimeric anti-FCV recombinant antibody. The obtained recombinant antibody is a novel antibody and is useful for the diagnosis, treatment and prevention of feline virus infections, particularly feline calicivirus infection, with high safety in administration into cats.